a16z

Vijay Pande's VZVC trades a16z scale for small, AI-driven bets

Former a16z biotech lead Vijay Pande has swapped a roughly $4 billion practice for a lean new firm, VZVC, where he plans just a handful of concentrated investments each year. He argues that open, shared datasets are key to unlocking AI's potential in medicine.